Geneva, Switzerland – February 03, 2017 – ObsEva SA (ObsEva) announced today that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
ObsEva SA Announces Pricing of Initial Public Offering
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva SA Announces Pricing of Initial Public Offering . Processed and transmitted by…
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
– First-in-class orally active prostaglandin F2α receptor antagonist designed to safely control inflammation, uterine contractions, membrane ruptures and cervical changes that…
ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI
Trial shows meaningful increase in pregnancy and live birth rates in patients treated with OBE001 ObsEva to proceed with a…
ObsEva Announces Plans to Conduct Initial Public Offering in the United States
GENEVA, SWITZERLAND, 17 October, 2016 – ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel…
ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis
– Clinical trial to assess safety and efficacy of novel GnRH antagonist in patients with pelvic pain associated with endometriosis…
2016 Wedbush PacGrow Healthcare Conference
ObsEva CEO & Co-Founder Ernest Loumaye will be presenting at the 2016 Wedbush PacGrow Healthcare Conference Date & Time: 17 August 2016…
ObsEva to Present at 2016 Wedbush Pacgrow Healthcare Conference
Geneva, Switzerland, 10 August 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…
ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2α Antagonist, for the Treatment of Preterm Labor
Geneva, Switzerland, 28 July 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to…